Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin

Toxicon

Volumn 73, Issue , 2013, Pages 9-16

  Torii, Yasushi ^a,b   Shinmura, Miho ^a   Kohda, Tomoko ^c   Kozaki, Shunji ^c   Takahashi, Motohide ^d   Ginnaga, Akihiro ^a  

^a Kaketsuken   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Osaka Prefecture University   (Japan)

^d PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

Author keywords

Botulinum antitoxin; Mouse neutralization test; Neutralization curves; Surface plasmon resonance; Toxin binding volume to antitoxin (L+ dose) measurement

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN A; BOTULINUM TOXIN A1; BOTULINUM TOXIN A1 ANTITOXIN; BOTULINUM TOXIN A2; BOTULINUM TOXIN A2 ANTITOXIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; DISSOCIATION; DRUG BINDING; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMORAL IMMUNITY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS; SERODIAGNOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; SPECIES DIFFERENCE; SURFACE PLASMON RESONANCE;

ANIMALS; BOTULINUM ANTITOXIN; BOTULINUM TOXINS, TYPE A; FEMALE; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; SPECIES SPECIFICITY; SURFACE PLASMON RESONANCE;

EID: 84880679295     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.06.020     Document Type: Article

References (24)

1. Arndt J.W., Jacobson M.J., Abola E.E., Forsyth C.M., Tepp W.H., Marks J.D., Johnson E.A., Stevens R.C. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 2006, 362(4):733-742.
2. Arnon S.S., Schechter R., Maslanka S.E., Jewell N.P., Hatheway C.L. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 2006, 354(5):462-471.
3. Bowmer E.J. Preparation and assay of the international standards for Clostridium botulinum types A, B, C, D and E antitoxins. Bull World Health Organ 1963, 29:701-709.
4. Center for Disease Control and Prevention Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers 1998, Center for Disease Control and Prevention, Atlanta.
5. Dover N., Barash J.R., Arnon S.S. Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes. J. Clin. Microbiol. 2009, 47(7):2349-2350.
6. East A.K., Bhandari M., Stacey J.M., Campbell K.D., Collins M.D. Organization and phylogenetic interrelationships of genes encoding components of the botulinum toxin complex in proteolytic Clostridium botulinum types A, B, and F: evidence of chimeric sequences in the gene encoding the nontoxic nonhemagglutinin component. Int. J. Syst. Bacteriol. 1996, 46(4):1105-1112.
7. Garcia-Rodriguez C., Levy R., Arndt J.W., Forsyth C.M., Razai A., Lou J., Geren I., Stevens R.C., Marks J.D. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat. Biotechnol. 2007, 25(1):107-116.
8. Henkel J.S., Jacobson M., Tepp W., Pier C., Johnson E.A., Barbieri J.T. Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 2009, 48(11):2522-2528.
9. Hill K.K., Smith T.J., Helma C.H., Ticknor L.O., Foley B.T., Svensson R.T., Brown J.L., Johnson E.A., Smith L.A., Okinaka R.T., Jackson P.J., Marks J.D. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J. Bacteriol. 2007, 189(3):818-832.
10. Jahn R., Niemann H. Molecular mechanisms of clostridial neurotoxins. Ann. N. Y. Aced. Sci. 1994, 733:245-255.
11. Jones R.G., Corbel M.J., Sesardic D. A review of WHO International Standards for botulinum antitoxins. Biologicals 2006, 34(3):223-226.
12. Kalb S.R., Lou J., Garcia-Rodriguez C., Geren I.N., Smith T.J., Moura H., Marks J.D., Smith L.A., Pirkle J.L., Barr J.R. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1,/A2, and/A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One 2009, 5(8):e12237.
13. Kozaki S., Nakaue S., Kamata Y. Immunological characterization of the neurotoxin produced by Clostridium botulinum type A associated with infant botulism in Japan. Microbiol. Immunol. 1995, 39(10):767-774.
14. Raffestin S., Couesnon A., Pereira Y., Mazuet C., Popoff M.R. Botulinum and tetanus neurotoxins, molecular biology and toxin gene regulation, mode of action. Clostridia: Morecular Biology in the Post-genomic Era 2009, 1-28. Caister Academic Press, Norfolk. H. Bruggemann, G. Gottschalk (Eds.).
15. Sakaguchi G., Ohishi I., Kozaki S. Purification and oral toxicities of Clostridium botulinum progenitor toxins. Biomedical Aspects of Botulism 1981, 21-34. Academic Press, New York. G.E. Lewis (Ed.).
16. Sakaguchi G. Clostridium botulinum toxins. Pharmacol. Ther. 1983, 19(2):165-194.
17. Sakaguchi G., Sakaguchi S., Kamata Y., Tabita K., Asao T., Kozaki S. Distinct characters of Clostridium botulinum type A strains and their toxin associated with infant botulism in Japan. Int. J. Food Microbiol. 1990, 11(3-4):231-241.
18. Shimizu T., Kondo H. Immunological difference between the toxin of a proteolytic strain and that of a nonproteolytic strain of Clostridium botulinum type B. Jpn. J. Med. Sci. Biol. 1973, 26(5-6):269-271.
19. Shimizu T., Kondo H., Sakaguchi G. Immunological heterogeneity of Clostridium botulinum type B toxins. Jpn. J. Med. Sci. Biol. 1974, 27(2):99-100.
20. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 1981, 33(3):155-188.
21. Smith T.J., Lou J., Geren I.N., Forsyth C.M., Tsai R., LaPorte S.L., Tepp W.H., Bradshaw M., Johnson E.A., Smith L.A., Marks J.D. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 2005, 73(9):5450-5457.
22. Torii Y., Tokumaru Y., Kawaguchi S., Izumi N., Maruyama S., Mukamoto M., Kozaki S., Takahashi M. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 2002, 20(19-20):2556-2561.
23. Torii Y., Takahashi M., Ishida S., Goto Y., Nakahira S., Harakawa T., Kaji R., Kozaki S., Ginnaga A. Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP). Toxicon 2010, 55(2-3):662-665.
24. Zhao H., Nakamura K., Kohda T., Mukamoto M., Kozaki Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms. Jpn. J. Infect. Dis. 2012, 65:138-145.